BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06068946 (VK2735 in Weight Loss): BVCT ex-ante prediction vs. reported outcome

On 15 Oct 2023, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 27 Feb 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT06068946
Acronym
VENTURE
Drug Name
VK2735
Drug MoA
GLP1R/GIPR-biased dual agonist
Drug Modality
synthetic peptide
Drug Class
Best-In-Class
Therapeutic Area
Nutritional and Metabolic Diseases
Indication
Weight Loss
Human Patients
176
Sponsor
Viking Therapeutics
Phase
Phase 2

Prediction of , index 1290

Prospective Prediction
Prediction Index
1290
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit superior to GSBR1289 and orforglipron)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
135 days in advance
Readout Data Interpretation
13.1% placebo-adjusted weight loss at week 13 vs 7% of tirzepatide at week 13; no plateau.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Phase
Phase 2
Status
Completed
Enrollment
176
Lead sponsor
Viking Therapeutics, Inc.
Conditions
Weight Loss
Interventions
BIOLOGICAL: VK2735; BIOLOGICAL: Placebo
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2023-08-31
Primary completion
2024-02-27
Completion
2024-04-02
Primary outcomes
  • Percent (relative) change from baseline to Week 13 in body weight (13 weeks)

NCT06068946 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials